Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTEND-Kids: BIVV001 in Pediatric Hemophilia A
NCT04759131Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Primary completion
- Jan 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 15
01
Overview
A Phase 3 trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Started Feb 2021; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04759131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759131.